The trial is taking place at:
R

Renstar Medical Research | Ocala, FL

Veeva-enabled site

A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis

Bristol-Myers Squibb (BMS) logo

Bristol-Myers Squibb (BMS)

Status and phase

Active, not recruiting
Phase 2

Conditions

Psoriasis

Treatments

Other: Placebo
Drug: BMS-986322

Study type

Interventional

Funder types

Industry

Identifiers

NCT05730725
U1111-1282-3606 (Registry Identifier)
2023-504848-34 (EudraCT Number)
IM032-041

Details and patient eligibility

About

The purpose of this study is to evaluate clinical effectiveness and safety of BMS-986322 in participants with moderate-to-severe psoriasis.

Enrollment

120 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

* Diagnosis of plaque psoriasis (PsO) for ≥ 6 months * Body mass index 18 to 40 kg/m\^2 and total body weight \> 50 kg (110 lbs) * Deemed by Investigator to be eligible for phototherapy or systemic therapy * Psoriatic plaques must cover ≥ 10% of body surface area at baseline * Psoriasis Area and Severity Index (PASI) score ≥ 12 and static Physician Global Assessment (sPGA) ≥ 3 at baseline

Exclusion criteria

* Diagnosis of non-plaque psoriasis (guttate, inverse, pustular, erythrodermic) * Diagnosis of uveitis, inflammatory bowel disease, or other immune-mediated conditions that are commonly associated with PsO for which a participant requires current systemic immunosuppressant medical treatment * Any significant acute or chronic medical illness Other protocol-defined inclusion/exclusion criteria apply

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

120 participants in 4 patient groups, including a placebo group

BMS-986322 Dose 1
Experimental group
Treatment:
Drug: BMS-986322
BMS-986322 Dose 2
Experimental group
Treatment:
Drug: BMS-986322
BMS-986322 Dose 3
Experimental group
Treatment:
Drug: BMS-986322
Placebo
Placebo Comparator group
Treatment:
Other: Placebo

Trial contacts and locations

40

Loading...

Central trial contact

First line of the email MUST contain NCT # and Site #.; BMS Study Connect Contact Center www.BMSStudyConnect.com

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems